00000nam 2200000zi 4500 9.913694 CaOODSP 20221214151124 m o d f cr cn||||||||| 220722e202206##onc ob f000 0 eng d 9780660447117 CaOODSP eng rda CaOODSP n-cn--- HP40-308/2022E-1-PDF Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. [Ottawa] : Public Health Agency of Canada = Agence de la santé publique du Canada, 2022. ©2022 1 online resource (151 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Cover title. "Publication date: June 2022." Publication copy replaced 2022-12-12 at request of authors. At head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). Issued also in French under title: Utilisation recommandée du palivizumab pour réduire les complications de l'infection par le virus respiratoire syncytial chez les nourrissons. Includes bibliographical references (pages 76-97). "The objective of this advisory committee statement is to review evidence and develop guidance on strategies to prevent severe consequences of RSV infection in children at high risk of severe RSV disease by administration of monoclonal antibody"--Guidance objective, page 8. Palivizumab Canada. Respiratory syncytial virus Canada. Infants Diseases Canada. Canada. National Advisory Committee on Immunization, issuing body. Utilisation recommandée du palivizumab pour réduire les complications de l'infection par le virus respiratoire syncytial chez les nourrissons. (CaOODSP)9.913695 Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. (CaOODSP)9.910768 PDF 1.36 MB https://publications.gc.ca/collections/collection_2022/aspc-phac/HP40-308-2022-eng-1.pdf 220345